Pfizer (NYSE:PFE) Trading Down 1.7% - What's Next?

Key Points

• Pfizer's shares dropped by 1.7% to a last traded price of $24.81, with trading volume increasing by 34% compared to the average session volume.
• Analysts have a consensus rating of "Hold" on Pfizer's stock, with a price target averaging $28.35 following various downgrades from firms like Wall Street Zen and Weiss Ratings.
• The company recently declared a $0.43 quarterly dividend, yielding 6.9% annually, with the payout ratio at 91.49% and the ex-dividend date set for November 7th.

Pfizer Inc. (NYSE:PFE - Get Free Report) shares traded down 1.7% on Friday . The company traded as low as $24.62 and last traded at $24.81. 62,709,553 shares were traded during trading, an increase of 34% from the average session volume of 46,922,590 shares. The stock had previously closed at $25.24.

Wall Street Analyst Weigh In

PFE has been the topic of a number of recent analyst reports. Weiss Ratings restated a "hold (c-)" rating on shares of Pfizer in a research report on Wednesday. Wall Street Zen downgraded shares of Pfizer from a "buy" rating to a "hold" rating in a research report on Sunday, September 28th. UBS Group reiterated a "neutral" rating and issued a $28.00 target price on shares of Pfizer in a report on Wednesday, October 1st. Citigroup boosted their target price on shares of Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Finally, Morgan Stanley dropped their target price on shares of Pfizer from $33.00 to $32.00 and set an "equal weight" rating on the stock in a report on Friday. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $28.35.

Pfizer Trading Down 1.7%

The company has a market cap of $141.03 billion, a price-to-earnings ratio of 13.19, a PEG ratio of 0.84 and a beta of 0.55. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The business's 50 day moving average price is $24.83 and its 200-day moving average price is $24.14.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.20. The company had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company's revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter last year, the firm earned $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.9%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer's payout ratio is 91.49%.

Institutional Trading of Pfizer

Several hedge funds and other institutional investors have recently made changes to their positions in PFE. GKV Capital Management Co. Inc. bought a new position in shares of Pfizer during the 1st quarter worth approximately $27,000. Curio Wealth LLC boosted its holdings in shares of Pfizer by 36,600.0% during the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 1,098 shares in the last quarter. Bayforest Capital Ltd bought a new position in shares of Pfizer during the 1st quarter worth approximately $28,000. North Capital Inc. bought a new position in shares of Pfizer during the 1st quarter worth approximately $28,000. Finally, Harbor Asset Planning Inc. bought a new position in shares of Pfizer during the 2nd quarter worth approximately $29,000. 68.36% of the stock is currently owned by institutional investors.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.